Health
Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy – News-Medical.net
Avacta Group plc, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co.Ltd and AffyXell Therapeutics.
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell Therapeutics, the joint venture established in South Korea by the two companies, to develop stem cell treatments incorporating Avacta’s neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future globa…
-
General22 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
General22 hours agoLithium mine closure shines light on Ravensthorpe community’s resilience
-
Noosa News21 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
General24 hours agoBack-to-back rate cuts tipped when Reserve Bank meets